Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 84 of 151

  1. MK-3475-02C

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  2. MK-3475-02D

    Merck Sharp and Dohme

    Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

    phase 2 small molecule active

    1 trial

  3. MK-3475-03A

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  4. MK-3475-03B

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  5. MK-3475-03C

    Merck Sharp and Dohme

    Clear cell renal cell carcinoma

    phase 2 small molecule active

    1 trial

  6. MK-3475-04B

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  7. MK-3475-04C

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  8. MK-3475-04D

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  9. MK-3475-06B

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  10. MK-3475-06C

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  11. MK-3475-06D

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  12. MK-3475-06E

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  13. MK-3475-365

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  14. MK-3475-495

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  15. MK-3475-667

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  16. MK-3475-B60

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  17. MK-3475-B98

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  18. MK-3475-B99

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  19. MK-3475A

    Merck Sharp and Dohme

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    phase 2 small molecule active

    1 trial

  20. MK-3475A-F11

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  21. MK-4830-002

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  22. MK-5592-127

    Merck Sharp and Dohme

    Fungal infection

    phase 2 small molecule active

    1 trial

  23. MK-5684-01A

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  24. MK-6024-017

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  25. MK-6070-002

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  26. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

  27. MK-7684A-005

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  28. MK-7902-009

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  29. MK-7902-013

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

  30. MK-7962-023

    Merck Sharp and Dohme

    Pulmonary Hypertension

    phase 2 small molecule active

    1 trial

  31. MK-7962-024

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  32. MK-7962-031

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  33. MK-8591-013

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  34. MK-9999-01C

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 small molecule active

    1 trial

  35. MK-9999-02A

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  36. MK0594

    VYNE Therapeutics

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  37. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  38. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  39. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  40. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  41. ML-004 (IR)/(ER) tablet

    MapLight Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule active

    2 trials

  42. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 small molecule active

    2 trials

  43. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  44. ML43332

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  45. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  46. MLN0264

    Takeda

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  47. MLN0264

    Takeda

    Adenocarcinoma of the Stomach

    phase 2 small molecule terminated

    1 trial

  48. MLN1202

    Takeda

    Atherosclerotic Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.